Nonprofit sues FDA to force Provenge approval

Share this article:
A nonprofit patient advocacy group has filed suit against the FDA in an Ohio federal court seeking to overturn the agency's decision earlier this year to not approve Dendreon's prostate cancer vaccine Provenge.

The lawsuit, filed by Ohio-based Care to Live, which includes some Dendreon investors, alleges that the FDA in May failed to follow an advisory committee recommendation to approve Provenge and instead asked the company for more information.

The group argues that Provenge's Biologics License Application approval was derailed by Richard Pazdur, director of the FDA drug center's oncologic drugs division, as part of a bureaucratic turf battle with the FDA's biologics center over who would control all oncology therapies.

It charges that this led him to place two conflicted panel members on an advisory committee that reviewed the drug.

The suit also alleges that FDA commissioner Andrew von Eschenbach was in support of an earlier biologics center recommendation to approve Provenge, but instead gave in to Pazdur's demands after he “executed a successful coup d'etat.”

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...